

**Amendments to the Specification:**

Please replace the table beginning on page 191, line 1 (Table 12), with the following amended table:

**Table 12: Comparative Antiviral Activity\* (EC<sub>50</sub>)**

|                               | BVDV               |                     | YFV                |                     |
|-------------------------------|--------------------|---------------------|--------------------|---------------------|
|                               | EC <sub>50</sub> * | CC <sub>50</sub> ** | EC <sub>50</sub> * | CC <sub>50</sub> ** |
| β-D-2'-CH <sub>3</sub> -riboG | 2                  | >100                | 1.2                | 20                  |
| β-D-2'-CH <sub>3</sub> -riboC | 3.7                | >100                | 70                 | >100                |
| β-D-2'-CH <sub>3</sub> -riboU | 20                 | >100                | 33                 | >100                |

\* Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT and YFV-BHK.

\*\* Compound concentration (μM) required to reduce the viability of cells by 50%.